L
Ludo Lavreys
Researcher at Tibotec
Publications - 8
Citations - 437
Ludo Lavreys is an academic researcher from Tibotec. The author has contributed to research in topics: Ritonavir & Lopinavir. The author has an hindex of 6, co-authored 8 publications receiving 424 citations.
Papers
More filters
Journal ArticleDOI
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Anthony M. Mills,Mark T. Nelson,Dushyantha Jayaweera,Kiat Ruxrungtham,Isabel Cassetti,Pierre Marie Girard,Cassy Workman,Inge Dierynck,Vanitha Sekar,Carline Vanden Abeele,Ludo Lavreys +10 more
TL;DR: Once-daily darunavir/ritonavir was both statistically noninferior and superior in virologic response to LPV/r, with a more favorable gastrointestinal and lipid profile, confirming DRV/ r as an effective, well tolerated, and durable option for antiretroviral-naive patients.
Journal ArticleDOI
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data
Mark T. Nelson,Pierre-Marie Girard,Pierre-Marie Girard,Ralph DeMasi,Liddy Chen,Erik Smets,Vanitha Sekar,Ludo Lavreys +7 more
TL;DR: Once-daily darunavir/ritonavir resulted in a higher virological response rate in suboptimally adherent patients compared with lopinavIR/rit onavir, in adherent and suboptimically adherent patients.
Journal ArticleDOI
Pharmacokinetics of Darunavir/Ritonavir and Rifabutin Coadministered in HIV-Negative Healthy Volunteers
Vanitha Sekar,Ludo Lavreys,Tom Van De Casteele,Cindy Berckmans,Sabrina Spinosa-Guzman,Tony Vangeneugden,Martine De Pauw,Richard M. W. Hoetelmans +7 more
TL;DR: It is suggested that DRV/r may be coadministered with RFB with a dose adjustment of RFB to 150 mg QOD and increased monitoring for RFB-related AEs, and it is not recommended to conduct further studies with this combination in healthy volunteers.
Journal ArticleDOI
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Erkki Lathouwers,Sandra De Meyer,Inge Dierynck,Tom Van De Casteele,Ludo Lavreys,Marie-Pierre de Béthune,Gaston Picchio +6 more
TL;DR: The findings of this resistance analysis confirmed the lack of development of major PI RAMs and the preservation of phenotypic susceptibility to all PIs in patients with VF.
Journal ArticleDOI
Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
TL;DR: Over 96 weeks, DRV/r had a similar effect on glucose and insulin levels but a more favourable lipid profile than LPV/ r in treatment-naïve, HIV-infected patients.